Cite
APA Citation
Devaux, A., Canon, J., Duhoux, F. P., Delrée, P., Galant, C., Coulie, P. G., Bar, I., Constant, M., Haussy, S., Bricard, O., Missault, K., Berlière, M., Willems, T., & Carrasco, J. (n.d.). 281TiPA phase Ib/II study of durvalumab combined with dose-dense EC in neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE). Annals of oncology, 29, . http://access.bl.uk/ark:/81055/vdc_100095497514.0x00003c